about
Management of trypanosomiasis and leishmaniasisThe anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasisDissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methodsChemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasisProcess of Fragment-Based Lead Discovery-A Perspective from NMRAnti-parasitic Peptides from Arthropods and their Application in Drug TherapyDevelopment and validation of a cytochrome c-coupled assay for pteridine reductase 1 and dihydrofolate reductaseNovel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteasesChemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosomeDihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein CrystallographyDiscovery of a Novel Class of Orally Active Trypanocidal N -Myristoyltransferase InhibitorsSelective inhibition of Biotin Protein Ligase from Staphylococcus aureusAssessment of Pseudomonas aeruginosa N5,N10-Methylenetetrahydrofolate Dehydrogenase - Cyclohydrolase as a Potential Antibacterial Drug TargetA Novel Allosteric Inhibitor of the Uridine Diphosphate N -Acetylglucosamine Pyrophosphorylase from Trypanosoma bruceiCrystal structures of IspF from Plasmodium falciparum and Burkholderia cenocepacia: comparisons inform antimicrobial drug target assessmentMuddled mechanisms: recent progress towards antimalarial target identificationDyes, trypanosomiasis and DNA: a historical and critical reviewLeishmanicidal metabolites from Cochliobolus sp., an endophytic fungus isolated from Piptadenia adiantoides (Fabaceae)Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90Mining a cathepsin inhibitor library for new antiparasitic drug leadsNeglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administrationThe R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.Investigation of trypanothione reductase as a drug target in Trypanosoma brucei.Comparative SILAC proteomic analysis of Trypanosoma brucei bloodstream and procyclic lifecycle stages.Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assayIdentification of ML251, a Potent Inhibitor of T. brucei and T. cruzi Phosphofructokinase.Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors.Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections.Structures, targets and recent approaches in anti-leishmanial drug discovery and development.Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa.Metabolic reprogramming during purine stress in the protozoan pathogen Leishmania donovaniTarget validation: linking target and chemical properties to desired product profileSchistosoma comparative genomics: integrating genome structure, parasite biology and anthelmintic discovery.Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library.Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosineKinetoplastids: related protozoan pathogens, different diseases.Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei.Global quantitative SILAC phosphoproteomics reveals differential phosphorylation is widespread between the procyclic and bloodstream form lifecycle stages of Trypanosoma brucei.
P2860
Q24596889-C417400E-685A-488D-BBA1-FE9C9D54E764Q24633734-EFF4460D-72A2-4904-AC96-B4B5F4B4720AQ24649110-7ABBF598-9448-430E-BA86-AF3273F781ADQ24657204-C316CDA9-65BD-4EB4-A273-3F8DACF13D34Q26738768-98F563B8-7CAC-42F5-82B7-677011D5934AQ26768112-7CF81DF4-EA41-4955-B768-5FC7812C1E8EQ27657419-4DE1AAED-10B0-4264-8400-A3603F3FD982Q27657523-32CD2CA6-1253-439B-868E-C752DAF106B9Q27671077-9D904D5F-F4B3-49C9-8B42-8AE073C093EAQ27671819-585B4148-626A-48A0-9BB6-52158ADA9A5AQ27676019-CD7E9CAA-BFFB-47E9-8A59-78AD39FADEE4Q27678137-E3A81188-9E1F-42E2-AB02-6442978995A0Q27678891-9C93E067-02F1-4223-8FDB-FCE1B5B04B38Q27678978-684BF03E-B59E-448D-9CCC-A06E4D1FB69FQ27681270-66F02579-2286-4ADF-BBD3-7A1B45E07BF2Q28066421-7F724562-721C-4BA0-830A-29114F439195Q28298491-228B934C-C15E-4687-A796-065C790D7C07Q28474272-C66AEF69-4004-4055-BBA3-06A993EB86B4Q28474428-0240C5A9-41F0-4C16-BC7A-B9D06E9F41B5Q28478016-82258C3D-1E6B-4A14-A00E-77AB4EDB4684Q28602660-B8F78945-FE4F-459D-8CA3-B473A3D10593Q30447200-A5D61AD4-26B9-4C2D-97C0-BD942991E1BAQ30897674-BE32F0EF-32A0-435D-B5E4-90835B37CE29Q31061421-B3E13C58-CA57-4B12-BCF7-3E57A438F6D8Q33604021-3D86D1A3-A2F3-497E-8D7F-2C45A90DDED4Q33636487-03B27354-366F-4D81-A8B8-C60D7DF1F319Q33653056-A5B7F7EC-5844-451C-8C57-52B607FFA699Q34097455-C3154AE9-1379-4EE9-8923-9884C073B964Q34975777-FC0A2740-5D66-491B-9F3A-BB26DA46C72FQ35012968-40D760BA-E3FA-4780-9149-281ABA189EF7Q35102950-A0846F72-2990-4C1E-A75F-D2FBBE4BF07FQ35105624-FAE3C26E-AB91-45C7-9CD6-6D24661EFB15Q35237566-359B67E6-5F18-406D-9956-DF2AB8D1673AQ35570876-4AB60AF3-8DFA-4BC9-8B7D-AC6E44C36592Q35592514-FD9FB5D0-1BD5-4345-BDC2-474D61C723DCQ35779255-B58C1232-42B0-46ED-BB1E-B19B176632BFQ36380098-E6AF6F5C-444B-4C3C-AE40-E20C7128E9B1Q36513308-B0BF96E2-7002-480E-ACC9-E07E030B06C4Q36753140-5DFECDC9-3788-43F0-B7F2-513A35B1188BQ36822445-77138986-4CEC-47A8-B3D8-359D60E987CB
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Target assessment for antiparasitic drug discovery.
@ast
Target assessment for antiparasitic drug discovery.
@en
Target assessment for antiparasitic drug discovery.
@nl
type
label
Target assessment for antiparasitic drug discovery.
@ast
Target assessment for antiparasitic drug discovery.
@en
Target assessment for antiparasitic drug discovery.
@nl
prefLabel
Target assessment for antiparasitic drug discovery.
@ast
Target assessment for antiparasitic drug discovery.
@en
Target assessment for antiparasitic drug discovery.
@nl
P2860
P50
P356
P1476
Target assessment for antiparasitic drug discovery.
@en
P2093
Julie A Frearson
P2860
P304
P356
10.1016/J.PT.2007.08.019
P577
2007-10-24T00:00:00Z